PROCUREMENT & SUPPLY CHAIN
EVERSANA | July 18, 2022
EVERSANA™, a pioneer of next-generation commercial services to the global life sciences industry with its Asian regional headquarters in Singapore and offices across Japan, China and other countries in the area, and Compai Pharma, an enterprising pharmaceutical company offering full-service commercialisation with offices in Singapore and Malaysia, today announced a strategic partnership to expand service across the Asia Pacific region.
Together, EVERSANA and Compai Pharma will provide medical and commercial resources to healthcare partners to support full market implementation and development for life science and pharmaceutical companies ready to expand into these markets.
"As the needs of clients and their patients continue to grow, so too do our capabilities to scale delivery on a global level, The Asia Pacific region is one of the fastest-growing pharmaceutical markets in the world and requires regional expertise to increase patient access. Together with Compai Pharma, we're now able to drive greater value and services for our clients to support their evolving commercialisation needs."
-Jim Lang, CEO, EVERSANA.
Capabilities available through the partnership include consulting, market access, medical awareness, education and communication, pharmacovigilance, marketing & sales excellence, as well as distribution and additional services.
"I am deeply honoured and excited to enter this partnership with such an esteemed company as EVERSANA, Our mission is to work closely with healthcare practitioners across APAC to ensure needed medications and devices are available for patients while also becoming a trusted partner to provide education and updates on the latest in clinical developments. This goal is highly synergistic with EVERSANA's global ambition."
-Tim Cushway, Founder and Director at Compai Pharma.
The partnership with Compai builds on EVERSANA's continued global growth, including recent expansion across the European Union and the United Kingdom. Additionally in June 2021, EVERSANA announced the growth of its medical communications and integrated compliance services across 18 European countries and in 10 local languages.
About Compai Pharma-
Compai Pharma was founded in 2017 with a headquarters in Singapore with a strong focus on healthcare business development focusing on medical, sales and marketing excellence. The company is governed by a lean and transparent management team, operating out of Singapore and Malaysia, that have experience and strong relationships across Australasia. The strategic imperative adopted by all members of the Compai team is to contribute in a dynamic, interactive and transparent manner building lasting partnerships. The initial focus has been with the introduction of a specialised high-dose IV iron, Monofer®, which has an important medical role across nearly all therapeutic areas – especially obstetrics and gynecology, surgery and anesthesia, cardiology, oncology, gastroenterology, and general practitioners – enabling strong networks and collaborations in both the private and public sectors. Compai is a Spanish word meaning 'friend' which characterizes our largely young, dynamic and passionate team that strives to bring first-class service to patients and our healthcare partners.
EVERSANA™ is the leading independent provider of global services to the life sciences industry. The company's integrated solutions are rooted in the patient experience and span all stages of the product life cycle to deliver long-term, sustainable value for patients, prescribers, channel partners and payers. The company serves more than 500 organizations, including innovative start-ups and established pharmaceutical companies, to advance life sciences solutions for a healthier world.
SINTX Technologies, Inc. | July 08, 2022
SINTX Technologies, Inc. (www.sintx.com) (NASDAQ: SINT) (“SINTX” or the “Company”), an original equipment manufacturer of advanced ceramics, announced the acquisition of Technology Assessment and Transfer, Inc. (TA&T; https://www.techassess.com/), significantly increasing SINTX’s capabilities in the aerospace, defense, and biomedical markets.
“We are excited to acquire TA&T and take another step towards diversifying and strengthening SINTX, TA&T will expand our use of advanced manufacturing technologies and introduce new ceramic material platforms to the SINTX portfolio. We expect the acquisition to bring immediate revenue to SINTX via TA&T’s well-established relationships with commercial partners and the U.S. government.”
-Dr. Sonny Bal, President and CEO of SINTX.
TA&T, based in Maryland, is a nearly 40-year-old advanced ceramics business that specializes in developing and commercializing a broad array of innovative materials for defense, biomedical, and industrial applications. The company’s technologies and products include 3D printing of ceramic medical devices and heat exchangers, chemical vapor infiltration and deposition of complex fiber-reinforced ceramic-matrix composites, and hot pressing of transparent armor and other technical ceramics. TA&T has a long track record of successfully winning research contracts and grants from the U.S. government and commercializing its innovative technologies.
As an example of TA&T’s innovation, ceramic heater bodies developed, designed, and manufactured by TA&T are a part of the Sample Analysis on Mars (SAM) instrument suite on board the Curiosity Rover (https://mars.nasa.gov/msl/home/). These oven heater bodies were manufactured by TA&T using Ceramic Stereolithography, a form of 3D printing and additive manufacturing, and can withstand the extreme temperatures of more than 1,500°F that are required to heat soil samples on Mars in hopes of detecting signs of life. TA&T was selected by NASA to make these parts because of the prohibitive cost of traditional manufacturing techniques.
“Technology Assessment and Transfer is excited about the opportunity that the SINTX acquisition provides for product growth in commercial, aerospace, and medical applications, The blend of federally-funded innovative technologies and SINTX’s business acumen is a compelling synergistic formula for future success.”
-Dr. Larry Fehrenbacher, Co-Founder and President of TA&T.
Dr. Mark Patterson, who worked with TA&T previously, and is currently Principal Scientist at Kratos SRE, commented that “In my view, the acquisition of TA&T by SINTX represents a significant opportunity to leverage complementary cultures and capabilities in the areas of advanced ceramics and innovation. TA&T has a long history of developing unique processes and ceramic materials for space, defense and commercial markets, and the company was an early developer of additively manufactured ceramic components for new ceramic markets. SINTX has complementary capabilities in biomedical devices and ceramic armor, with access to capital markets and organizational skills that will greatly help to mature and transition these technologies. I am excited to see what will come from this promising synergy, and hope that we will get to experience more ceramic products transitioned to end users.”
Ascendiant Capital Markets LLC served as the sole M&A Advisor on the transaction.
About SINTX Technologies, Inc.
SINTX Technologies is an OEM ceramics company that develops and commercializes advanced ceramics for medical and non-medical applications. The core strength of SINTX Technologies is the manufacturing, research, and development of ceramics for external partners. The Company presently manufactures silicon nitride powders and components in its FDA registered, ISO 13485:2016 certified, and ASD9100D certified manufacturing facility. For more information on SINTX Technologies or its advanced ceramics material platforms, please visit www.sintx.com.
About Technology Assessment and Transfer, Inc.
Technology Assessment and Transfer, Inc. (TA&T) is a high technology small business that specializes in development of advanced, materials-oriented technologies for aerospace, defense, bio-medical and industrial applications. TA&T uses government research grants to support advanced technology research and development innovations and commercialize via limited production, technology licensing and cooperative partnerships. TA&T provides a host of services that includes 3D printing, PVD-CVD coatings, material processing-CMCs, CIP, PS, HP, HIP and material characterization for powders and finished parts-TGA/DSC, PSD. SA, Dilatometry, UV-VIS and FTIR transmission, haze and clarity.
General Motors | July 27, 2022
Livent and General Motors Co. announced today a significant multi-year sourcing agreement in which Livent will supply GM with battery-grade lithium hydroxide made primarily from lithium extracted at Livent's brine-based operations in South America. Lithium hydroxide is crucial to GM's plans to make higher performance, higher mileage EVs. The lithium hydroxide from Livent will be used in GM's Ultium battery cathodes, which will power electric vehicles such as the recently revealed Chevrolet Blazer EV, Chevrolet Silverado EV, GMC HUMMER EV and Cadillac LYRIQ.
Livent will provide battery-grade lithium hydroxide to GM over a six-year period beginning in 2025. Over the course of the agreement, Livent will increasingly supply battery-grade lithium hydroxide to GM from its manufacturing facilities in the U.S., with the goal of transitioning 100% of Livent's downstream lithium hydroxide processing for GM to North America. The agreement is expected to help secure supply for GM while assisting Livent in expanding its North American capabilities.
Both GM and Livent share a commitment to responsible operations and sustainable supply chains through industry and multi-stakeholder platforms. General Motors is a member of the Responsible Minerals Initiative (RMI), joined the Initiative for Responsible Mining Assurance (IRMA) in 2021 and plans to become carbon neutral in global products and operations by 2040. Livent is actively engaged in an IRMA third-party assessment, has a gold rating from EcoVadis for sustainability and has announced a goal of overall carbon neutrality by 2040.
"We are building a strong, sustainable, scalable and secure supply chain to help meet our fast-growing EV production needs, We will further localize the lithium supply chain in North America over the course of the agreement. In addition, it is aligned with our approach to responsible sourcing and supply chain management and demonstrates our commitment to strong supplier relationships. GM now has contractual commitments secured with strategic partners for all battery raw material to support our goal of 1 million units of EV capacity by the end of 2025"
-Jeff Morrison, vice president, Global Purchasing and Supply Chain, GM.
Paul Graves, president and chief executive officer of Livent commented, We are excited to begin this long-term relationship with GM, one of the most iconic brands in the automotive industry and a leading force in the transition to electrification. With a shared commitment to sustainability and responsible operations, we look forward to building a broad partnership that will support GM's electric vehicle strategy, its supply chain goals and the future requirements of its growing EV fleet for reliable, high-performance lithium products.
About General Motors-
General Motors (NYSE:GM) is a global company focused on advancing an all-electric future that is inclusive and accessible to all. At the heart of this strategy is the Ultium battery platform, which powers everything from mass-market to high-performance vehicles. General Motors, its subsidiaries and its joint venture entities sell vehicles under the Chevrolet, Buick, GMC, Cadillac, Baojun and Wuling brands. More information on the company and its subsidiaries, including OnStar, a global leader in vehicle safety and security services, can be found at https://www.gm.com.
Livent (NYSE: LTHM) is a fully integrated lithium company with a rich heritage of innovation and a long, proven history of producing performance lithium compounds. For nearly eight decades, Livent has partnered with its customers to safely and sustainably use lithium to power the world. Livent is one of only a small number of companies with the capability, reputation, and know-how to produce high-quality finished lithium compounds that are helping meet the growing demand for lithium. The company has one of the broadest product portfolios in the industry, powering demand for green energy, modern mobility, the mobile economy, and specialized innovations, including light alloys and lubricants.